CRDL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.100

+11.11%

-0.105

+5%

-0.105

+5%

Estimates Revision

The market is revising No Change the revenue expectations for Cardiol Therapeutics Inc. (CRDL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.48%.

EPS Estimates for FY2025

Revise Upward

+2%

In Past 3 Month

Stock Price

Go Down

-6.48%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.25 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

8.25

High

10.00

Current: 0.000

Low

6.00

Averages

8.25

High

10.00

H.C. Wainwright

Buy

initiated

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-07

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-02-24

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-02-24

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.29, compared to its 5-year average forward P/E of -4.07. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.07

Current PE

-3.29

Overvalued PE

-2.20

Undervalued PE

-5.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.66

Current EV/EBITDA

-4.43

Overvalued EV/EBITDA

-0.83

Undervalued EV/EBITDA

-6.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.36

Current PS

0.00

Overvalued PS

91.24

Undervalued PS

-44.51

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRDL News & Events

Events Timeline

No data

News

2.0

2025-12-02Benzinga

MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading

4.0

2025-12-01Benzinga

HC Wainwright & Co. Affirms Buy Rating for Cardiol Therapeutics, Keeps $9 Price Target Intact

9.0

2025-07-22NASDAQ.COM

Cardiol To Report ARCHER Study Data Within The Next Two Weeks

People Also Watch

Frequently Asked Questions

What is Cardiol Therapeutics Inc (CRDL) stock price today?

The current price of CRDL is 1.01 USD — it has increased 0 % in the last trading day.

What is Cardiol Therapeutics Inc (CRDL)'s business?

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

What is the price predicton of CRDL Stock?

What is Cardiol Therapeutics Inc (CRDL)'s revenue for the last quarter?

Cardiol Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Cardiol Therapeutics Inc (CRDL)'s earnings per share (EPS) for the last quarter?

Cardiol Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for Cardiol Therapeutics Inc (CRDL)'s fundamentals?

How many employees does Cardiol Therapeutics Inc (CRDL). have?

Cardiol Therapeutics Inc (CRDL) has 18 emplpoyees as of January 08 2026.

What is Cardiol Therapeutics Inc (CRDL) market cap?

Today CRDL has the market capitalization of 101.00M USD.